Avicanna (TSE:AVCN)
TSX:AVCN
Earnings Data
Report Date
May 18, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
<0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized material operational and scientific progress—improved gross margins (53%, +10 pts), reduced operating expenses (–9%), stronger liquidity (working capital +23%), R&D/IP milestones (PwdRX/data and new USPTO patent), and clinical advancements (450 patient RWE study published; Phase II underway). These positives were tempered by flat top-line revenue at $25.5M, a still-negative full-year adjusted EBITDA (–$300k) and net loss ($2.7M), early-stage commercial launches (soft launch of Trunerox) and ongoing regulatory and market uncertainties (U.S. rescheduling dependency and stock overhang). On balance, the company presented clear momentum on margins, efficiency, IP and clinical programs while acknowledging remaining commercialization and market-risk headwinds.Company Guidance
Stable Revenue with Improved Profitability
Total revenue of $25.5M in 2025, essentially flat year-over-year, accompanied by improved profitability metrics: gross profit of $13.5M and a gross margin of 53% (up 10 percentage points from 48% in 2024).
Significant Adjusted EBITDA and Net Loss Improvements
Adjusted EBITDA improved 71% year-over-year to a full-year loss of $300k (Q4 2025 achieved positive adjusted EBITDA of $310k). Net loss reduced by 41% from $4.6M in 2024 to $2.7M in 2025.
Operating Expense and Working Capital Improvements
Operating expenses decreased by $1.5M (a 9% reduction year-over-year). Working capital position improved by 23% in 2025, signaling stronger short-term liquidity management.
Low Leverage and Reduced External Financing
Company carries no structured debt on the balance sheet and raised only $1M via a non-brokered private placement in 2025 (versus $4.8M in 2024), reflecting reduced reliance on external capital.
Commercial Footprint and MyMedi Momentum
Expanded commercial presence with ~50 SKUs in the Canadian market and 170 listings (a 26% increase from prior year). Avicanna-branded product sell-through on MyMedi grew from 17.5% (Q4 2024) to 19.7% (Q4 2025), a ~12% increase year-over-year as a percent of MyMedi sales.
International Market Entry and Aureus Enhancements
Entered the company's 24th international market and expanded exports to Europe and Australia; international segment (Santa Marta Golden JV) generated $1.9M. Aureus (Colombia) improved quality and organic premium flower production to support export demand.
R&D and IP Milestones
Finalized two proprietary self-emulsifying drug delivery platforms (in fluid and PwdRX). PwdRX demonstrated in vitro improvements vs. MCT oil: +74% bioavailability, +63% increase in peak plasma concentration, and +134% higher peak concentration. Filed a provisional patent for PwdRX and received a new USPTO patent for a topical cannabinoid composition.
Clinical Evidence Generation
National real-world evidence study enrolled ~450 patients and was published in the Canadian Journal of Pain showing significant improvements across multiple endpoints over 24 weeks. Initiated a Phase II randomized placebo-controlled trial in osteoarthritic pain (recruiting) and received Health Canada approval for a Phase I dose-finding study.
TSE:AVCN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:AVCN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 01, 2026 | C$0.15 | C$0.15 | 0.00% |
Nov 14, 2025 | C$0.26 | C$0.23 | -11.76% |
Aug 13, 2025 | C$0.28 | C$0.27 | -5.26% |
May 14, 2025 | C$0.24 | C$0.28 | +18.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Avicanna (TSE:AVCN) report earnings?
Avicanna (TSE:AVCN) is schdueled to report earning on May 18, 2026, After Close (Confirmed).
What is Avicanna (TSE:AVCN) earnings time?
Avicanna (TSE:AVCN) earnings time is at May 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:AVCN EPS forecast?
Currently, no data Available